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Delays in publication of cost utility analyses conducted
alongside clinical trials: registry analysis
Dan Greenberg, Allison B Rosen, Natalia V Olchanski, Patricia W Stone, John Nadai,
Peter J Neumann
Economic evaluations conducted alongside ran-
domised controlled trials enable analysis of detailed,
patient level data on efficacy, cost, and quality of life in
a controlled setting. They can provide timely and
reliable assessments of value for money, to inform
decisions on coverage and reimbursement.1–3
The BMJ recently decided to consider trial based
economic evaluations for publication only if the clinical
results are submitted to the journal as well.4 We assessed
the extent to which cost utility analyses are conducted
alongside trials, estimated the time lag between the pub-
lication of trials’ clinical and economic results, and com-
pared the characteristics of journals publishing the
clinical trial data and the cost utility analyses.
Methods and results
We conducted a systematic search for original English
language cost utility analyses published in 1976-2001
by using Medline and other electronic databases. Two
readers independently reviewed each study and came
to a consensus on whether the analysis was conducted
alongside a trial (data on both efficacy and resource
use from the trial were used for the analysis). We iden-
tified the journal and publication date for each cost
utility analysis and the corresponding trial. To assess
the study’s potential readership and dissemination we
used paired sample t tests to compare the mean impact
factors of journals in which studies were published and
the extent to which publications were subsequently
cited by other authors.
Of 533 cost utility analyses identified, 45 (8%) were
trial based economic evaluations and covered a variety
of clinical areas, particularly cardiovascular disease,
cancer, and psychiatry (a full list of studies is available
at www.hsph.harvard.edu/cearegistry). We could not
determine the lag in publication between the trial and
the economic evaluation for four studies, for which a
specific trial could not be identified or trial results were
published only in abstract form. In cases where the
clinical trial results and economic evaluation were
reported in the same article or in the same issue of the
journal (n = 7), we assumed no lag.
On average, cost utility analyses were published
almost two years after the publication of the
corresponding trial (mean (SD) 1.8 (1.4) years; range
0-7.5 years) (figure). Journal impact factors were higher
for trials than for cost utility analyses (11.0 v 4.9;
t= − 3.951 (df = 28); 95% confidence interval for the
difference − 9.25 to − 2.93; P < 0.001). The mean
number of citations per year (total number of citations
divided by number of years since the study was
published) was also higher for clinical trials than for
the economic evaluations (27.4 v 3.4; t= − 3.197
(df = 30); 95% confidence interval for the difference
− 39.24 to − 8.64; P = 0.003).
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than 75% of cost utility analyses were published one year or more
after publication of the trial’s clinical results
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Comment
We found a substantial delay in the publication of cost
utility analyses, suggesting that reliable economic data
are usually not available, at least in peer reviewed
journals, for decision makers when decisions on
adoption and reimbursement are typically made.
Moreover, compared with trial results, dissemination of
cost utility analyses takes place in journals with lower
readership and influence. Several factors may contribute
to this phenomenon: economic evaluations may be time
consuming to construct, as they typically involve projec-
tions of trial data over time and across populations
through use of modelling techniques and data from
external sources; trial sponsors and investigators are
eager to report important clinical results first, and more
resources are initially allocated to interpreting and pub-
lishing these results; given that most readers of clinical
journals are physicians, and not economists or policy
makers, manuscripts presenting important clinical
results are more often assigned by editors to an acceler-
ated review and publication process.
Efforts have recently been made to keep the clinical
and economic results of a trial together.4 Further
efforts (for example, fast track review process) should
be made to promote timely dissemination of results of
economic evaluations concurrent with or soon after
the completion and publication of the trial.
We thank Richard H Chapman for his contribution to the
design and analysis of the Harvard School of Public Health
Cost-Effectiveness Analysis Registry.
Contributors: DG had the original idea for the study, drafted the
first version of the manuscript, did the statistical analysis, and is
the guarantor. All authors extracted data, interpreted the findings,
critically revised the report, and approved the final version.
Funding: Supported by grant number R01 HS10919 from the
Agency for Health Care Research and Quality.
Competing interests: None declared.
1 Gold M, Siegel J, Russel L, Weinstein M, eds. Cost-effectiveness in health and
medicine. New York: Oxford University Press, 1996.
2 Drummond M. Introducing economic and quality of life measurements
into clinical studies. Ann Med 2001;33:344-9.
3 Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the
economic evaluation of health care programmes. 2nd ed. New York: Oxford
University Press, 1997.
4 Smith R. New BMJ policy on economic evaluations. BMJ 2002;325:1124.
(Accepted 30 January 2004)
doi 10.1136/bmj.38079.502326.AE
Guillain-Barré syndrome seen in users of isotretinoin
J Pritchard, R Appleton, R Howard, R A C Hughes
We report Guillain-Barré syndrome in people taking oral
isotretinoin, a retinoid drug used in secondary care for
severe acne.1 The Committee on Safety of Medicines has
received one other report of Guillain-Barré syndrome
after oral isotretinoin (Committee on Safety of
Medicines, private communication).
Case 1—A 31 year old man took 80 mg of oral
isotretinoin a day for five weeks, during which he had
epistaxis, dry lips, cough, and arthralgia before
developing paraesthesiae in his feet and influenza-like
symptoms. The next day he could not stand due to an
areflexic tetraparesis and needed ventilatory support.
Within four days he could only blink.
Case 2—A 13 year old boy took 50 mg of oral
isotretinoin a day for two months, stopped for one week,
and then took 30 mg a day for six weeks but had
epistaxis, lethargy, and headaches. After stopping
isotretinoin again for 10 days he developed a flaccid
areflexic tetraparesis needing ventilatory support.
Both patients displayed cerebrospinal fluid
albuminocytological dissociation. Nerve conduction
studies in case 1 showed a motor axonal neuropathy with
unrecordable sensory potentials and F waves, those in
case 2, done after 21 months, showed borderline
increased F wave latencies. Both patients received
intravenous immunoglobulin IVIg 2 g/kg and left
hospital within three months. Neither patient has been
rechallenged with oral isotretinoin, although the first
continued to use topical isotretinoin gel 0.05% which is
not absorbed.
Retinoids affect the development, differentiation, and
function of the central nervous system. Sensory
neuropathy has been described in patients taking the
retinoid drug acitretin.2 Over a 19 year period, an
estimated 375 000 patients have been treated with oral
isotretinoin in the United Kingdom (Roche, personal
communication), and the annual incidence of
Guillain-Barré syndrome is about 2 in 100 000. This is
insufficient to establish a causal association between
Guillain-Barré syndrome and isotretinoin. We hope to
alert others to report similar cases.
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What is already known on this topic
To identify cost effective interventions, decision
makers need timely and reliable information
about the clinical and economic consequences of
treatments
Economic evaluations conducted alongside
clinical trials enable analysis of detailed, patient
level data on efficacy, cost, and quality of life in a
controlled setting
What this study adds
A substantial delay in the publication of economic
evaluations suggests that reliable economic data
are usually not available when decisions have to be
made
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